SuperworthRadNet EPS RDNT
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.27
- Latest quarter, Q2 FY26
- $0.10
- −47% on a year earlier
- Fiscal year 2025
- −$0.26
- −967% on the year before
RadNet's earnings per share was −$0.27 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.10, down 47% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.26 | −967% |
| FY2024 | $0.03 | n/a |
| FY2023 | −$0.02 | −112% |
| FY2022 | $0.17 | −63% |
| FY2021 | $0.46 | n/a |
| FY2020 | −$0.30 | −203% |
| FY2019 | $0.29 | −55% |
| FY2018 | $0.65 | n/a |
| FY2017 | $0.00 | −100% |
| FY2016 | $0.16 | −6% |
| FY2015 | $0.17 | +750% |
| FY2014 | $0.02 | −67% |
| FY2013 | $0.06 | −96% |
| FY2012 | $1.62 | +753% |
| FY2011 | $0.19 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.10 | −47% | −$0.27 | |
| Q1 FY26 | −$0.43 | n/a | −$0.18 | |
| Q4 FY25 | −$0.01 | −114% | −$0.26 | |
| Q3 FY25 | $0.07 | +75% | −$0.18 | |
| Q2 FY25 | $0.19 | n/a | −$0.21 | |
| Q1 FY25 | −$0.51 | n/a | −$0.44 | |
| Q4 FY24 | $0.07 | n/a | $0.03 | |
| Q3 FY24 | $0.04 | −84% | −$0.07 | |
| Q2 FY24 | −$0.04 | −133% | $0.14 | |
| Q1 FY24 | −$0.04 | n/a | $0.30 | |
| Q4 FY23 | −$0.03 | n/a | −$0.02 | |
| Q3 FY23 | $0.25 | +2400% | −$0.01 |
Against its peers
Companies in Medical - Diagnostics & Research nearest RadNet's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RDNTRadNet | −$0.27 | |
| BLLNBillionToOne | $0.65 | |
| LNTHLantheus | $4.13 | +10% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| CDNACareDx | $2.07 | +116% a year |
| CAICaris Life Sciences | $0.37 | |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| Peer median | $3.12 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on RadNet
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.